Loading...

Intellia Therapeutics, Inc. Peer Comparison

Metric Value Ranking
Market Cap $968.6 Million 4/10 VRTX
$117.2B
CRSP
$3.7B
BEAM
$2.4B
NTLA
$968.6M
DNA
$708.1M
VERV
$661.2M
SANA
$634.1M
FATE
$142.4M
CRBU
$116.8M
EDIT
$98.2M
Gross Margin 100% 1/10 NTLA
100%
FATE
100%
CRBU
100%
DNA
89%
VRTX
86%
VERV
74%
BEAM
62%
SANA
0%
EDIT
-100%
CRSP
-100%
Profit Margin -100% 4/10 VRTX
38%
SANA
0%
DNA
-63%
NTLA
-100%
EDIT
-100%
FATE
-100%
CRSP
-100%
BEAM
-100%
CRBU
-100%
VERV
-100%
EBITDA margin -1490% 6/10 VRTX
40%
DNA
-62%
SANA
-100%
BEAM
-639%
VERV
-829%
NTLA
-1490%
FATE
-1704%
CRBU
-1889%
CRSP
-18294%
EDIT
-101870%
Quarterly Revenue $9.1 Million 4/10 VRTX
$2.8B
DNA
$89.0M
BEAM
$14.3M
NTLA
$9.1M
VERV
$6.9M
FATE
$3.1M
CRBU
$2.0M
CRSP
$602,000
EDIT
$61,000
SANA
$0
Quarterly Earnings -$135.7 Million 10/10 VRTX
$1.0B
CRBU
-$34.7M
FATE
-$47.7M
VERV
-$50.1M
DNA
-$56.4M
SANA
-$59.9M
EDIT
-$62.1M
CRSP
-$85.9M
BEAM
-$96.7M
NTLA
-$135.7M
Quarterly Free Cash Flow -$86.1 Million 7/10 VRTX
$1.5B
FATE
-$29.9M
CRBU
-$33.3M
VERV
-$40.5M
EDIT
-$55.5M
SANA
-$55.9M
NTLA
-$86.1M
BEAM
-$89.7M
CRSP
-$107.1M
DNA
-$118.6M
Trailing 4 Quarters Revenue $43.1 Million 6/10 VRTX
$10.6B
BEAM
$349.6M
DNA
$218.0M
CRSP
$201.6M
EDIT
$61.8M
NTLA
$43.1M
VERV
$24.4M
FATE
$13.4M
CRBU
$11.5M
SANA
$0
Trailing 4 Quarters Earnings -$522.3 Million 9/10 VRTX
$2.8B
DNA
$89.0M
BEAM
$14.3M
NTLA
$9.1M
VERV
$6.9M
FATE
$3.1M
CRBU
$2.0M
CRSP
$602,000
EDIT
$61,000
SANA
-$0
Quarterly Earnings Growth -11% 7/10 DNA
81%
CRSP
23%
VRTX
1%
BEAM
-1%
FATE
-6%
VERV
-10%
NTLA
-11%
EDIT
-38%
CRBU
-247%
SANA
-6190%
Annual Earnings Growth -6% 7/10 BEAM
58%
CRSP
31%
DNA
21%
SANA
10%
FATE
8%
VERV
5%
NTLA
-6%
EDIT
-27%
CRBU
-50%
VRTX
-113%
Quarterly Revenue Growth -24% 9/10 VERV
120%
DNA
61%
FATE
58%
VRTX
12%
EDIT
0%
CRSP
0%
SANA
0%
BEAM
-17%
NTLA
-24%
CRBU
-91%
Annual Revenue Growth -18% 8/10 EDIT
613%
BEAM
351%
FATE
184%
VERV
160%
VRTX
7%
SANA
0%
CRSP
-4%
NTLA
-18%
DNA
-27%
CRBU
-67%
Cash On Hand $120.5 Million 7/10 VRTX
$5.2B
DNA
$616.2M
BEAM
$230.2M
CRSP
$225.7M
VERV
$158.7M
SANA
$127.0M
NTLA
$120.5M
EDIT
$95.8M
FATE
$37.9M
CRBU
$32.0M
Short Term Debt $19.2 Million 1/10 NTLA
$19.2M
CRSP
$16.9M
EDIT
$16.4M
BEAM
$12.9M
SANA
$10.6M
VERV
$10.4M
FATE
$6.9M
CRBU
$1.2M
VRTX
-$0
DNA
-$0
Long Term Debt $82.4 Million 7/10 VRTX
$1.7B
DNA
$445.6M
BEAM
$298.3M
CRSP
$210.7M
FATE
$92.1M
SANA
$85.5M
NTLA
$82.4M
VERV
$60.9M
CRBU
$25.5M
EDIT
$22.1M
PE -1.00 1/10 NTLA
-1.00
VRTX
-1.00
EDIT
-1.00
FATE
-1.00
CRSP
-1.00
BEAM
-1.00
SANA
-1.00
CRBU
-1.00
VERV
-1.00
DNA
-1.00
PS 22.48 2/10 VERV
27.10
NTLA
22.48
CRSP
18.33
VRTX
11.05
FATE
10.59
CRBU
10.18
BEAM
6.77
DNA
3.25
EDIT
1.59
SANA
-1.00
PB 1.01 6/10 VRTX
7.50
BEAM
2.99
SANA
2.17
CRSP
1.91
VERV
1.30
NTLA
1.01
DNA
0.89
EDIT
0.56
CRBU
0.42
FATE
0.39
PC 8.04 4/10 VRTX
22.38
CRSP
16.38
BEAM
10.28
NTLA
8.04
SANA
4.99
VERV
4.17
FATE
3.76
CRBU
3.65
DNA
1.15
EDIT
1.03
Liabilities to Equity 0.22 8/10 SANA
0.91
EDIT
0.87
DNA
0.86
BEAM
0.48
VRTX
0.42
FATE
0.37
VERV
0.31
NTLA
0.22
CRBU
0.22
CRSP
0.16
ROA -0.45 8/10 VRTX
-2%
CRSP
-11%
BEAM
-12%
VERV
-30%
FATE
-38%
CRBU
-43%
DNA
-44%
NTLA
-45%
SANA
-55%
EDIT
-64%
ROE -0.54 7/10 VRTX
-3%
CRSP
-12%
BEAM
-18%
VERV
-39%
FATE
-52%
CRBU
-53%
NTLA
-54%
DNA
-82%
SANA
-105%
EDIT
-120%
Current Ratio 5.57 2/10 CRSP
7.13
NTLA
5.57
CRBU
5.45
VERV
4.27
FATE
3.73
VRTX
3.36
BEAM
3.08
DNA
2.17
EDIT
2.16
SANA
2.10
Quick Ratio 3.12 4/10 NTLA
-1.00
VRTX
-1.00
EDIT
-1.00
FATE
-1.00
CRSP
-1.00
BEAM
-1.00
SANA
-1.00
CRBU
-1.00
VERV
-1.00
DNA
-1.00
Long Term Debt to Equity 0.09 9/10 DNA}
0.56
BEAM}
0.38
SANA}
0.29
FATE}
0.25
EDIT}
0.13
VERV}
0.12
VRTX}
0.11
CRSP}
0.11
NTLA}
0.09
CRBU}
0.09
Debt to Equity 0.11 8/10 DNA
0.56
SANA
0.33
FATE
0.27
EDIT
0.22
BEAM
0.20
VERV
0.14
CRSP
0.12
NTLA
0.11
VRTX
0.11
CRBU
0.09
Burn Rate 0.84 8/10 DNA
8.30
VERV
2.88
CRSP
2.29
BEAM
2.06
SANA
1.92
EDIT
1.43
CRBU
0.89
NTLA
0.84
FATE
0.71
VRTX
-5.36
Cash to Cap 0.12 7/10 EDIT
0.98
DNA
0.87
FATE
0.27
CRBU
0.27
VERV
0.24
SANA
0.20
NTLA
0.12
BEAM
0.10
CRSP
0.06
VRTX
0.04
CCR 0.63 9/10 DNA
2.10
VRTX
1.43
CRSP
1.25
CRBU
0.96
BEAM
0.93
SANA
0.93
EDIT
0.89
VERV
0.81
NTLA
0.63
FATE
0.63
EV to EBITDA -7.00 6/10 VRTX}
101.86
EDIT}
-0.66
SANA}
-1.00
CRBU}
-2.92
FATE}
-3.88
NTLA}
-7.00
DNA}
-9.74
VERV}
-10.08
BEAM}
-25.20
CRSP}
-33.58
EV to Revenue 22.04 2/10 VERV
23.52
NTLA
22.04
CRSP
18.34
FATE
15.13
VRTX
10.72
CRBU
9.72
BEAM
6.57
DNA
2.47
EDIT
0.66
SANA
-1.00